InterCure Ltd. Announces Proposed VoluntaryDelisting from the Toronto Stock Exchangeand shallcontinue to be listed on the NASDAQ and TASE

Jul 10, 2024

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

May 22, 2024

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

May 1, 2024